21.40USD+2.20%Mkt Cap: 1.35B $P/E: —1d ago
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provi…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap1.35B $
Enterprise Value374.16M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-109.17M $
Revenue/Share—
Last Price21.40 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.34
EV/Revenue—
P/S—
P/B-0.50
EPS (TTM)-2.59
EPS (Forward)—
52W Range
17.2280% of range22.47
52W High22.47 USD
52W Low17.22 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE47.12%
ROA-144.56%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-97.56M $
CapEx (TTM)136.00K $
FCF Margin—
FCF Yield—
Net Debt-41.62M $
Net Debt/EBITDA0.37
Balance Sheet
Debt/Equity-0.00
Current Ratio3.23
Quick Ratio2.91
Book Value/Sh-42.4940 USD
Cash/Share7.096 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.63.24M
Float2.62M
Insiders5.49%
Institutions82.99%
Technical
SMA 5019.59 (+9.2%)
SMA 20019.59 (+9.2%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)594.80K
Avg Vol (10d)560.88K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—